← Human Trials & Peer-Reviewed Studies
Zinc supplementation and stunted infants in Ethiopia: a randomised controlled trial.
Plain-language guide to PMID 10885352 (2000): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.
Key Facts
- PMID
- 10885352
- Journal
- Lancet (London, England)
- Year
- 2000
- Study type
- Randomized Controlled Trial
- Authors
- Umeta M et al. (5 authors)
- DOI
- 10.1016/S0140-6736(00)02348-5
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.
Stunting is highly prevalent in Ethiopia and many other developing countries but the reason for it is poorly understood.
Zinc is essential for growth but diets in such countries often do not contain zinc in sufficient quantity or of sufficient bioavailability.
Who Took Part
By PubMed's age tags, the people studied were infants and adults, both men and women.
A randomised, double-blind, placebo-controlled trial was done on apparently healthy breastfed infants aged 6-12 months. 100 non-stunted (length-for-age, Z score < -2) were matched for age and sex with 100 randomly selected stunted (> -2) infants.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.
Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.
Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.
What Was Measured
PubMed files the paper under topics including Analysis of Variance, Anthropometry, Breast Feeding, Dietary Supplements, Ethiopia, Growth Disorders and Maternal Age.
The authors tagged it with the keywords Africa, Africa South Of The Sahara, Age Factors, Biology, Child Development and Clinical Research.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2000 (Lancet (London, England)), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.